Dynabac en es it fr

Dynabac Brand names, Dynabac Analogs

Dynabac Brand Names Mixture

  • No information avaliable

Dynabac Chemical_Formula


Dynabac RX_link


Dynabac fda sheet

Dynabac msds (material safety sheet)

Dynabac Synthesis Reference

No information avaliable

Dynabac Molecular Weight

835.074 g/mol

Dynabac Melting Point

No information avaliable

Dynabac H2O Solubility


Dynabac State


Dynabac LogP


Dynabac Dosage Forms

Tablets (enteric coated, 250mg)

Dynabac Indication

For the treatment of the following mild-to-moderate infections caused by susceptible strains of microorganisms: acute bacterial exacerbations of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsilitis, and uncomplicated skin and skin structure infections.

Dynabac Pharmacology

Dirithromycin is a pro-drug which is converted non-enzymatically during intestinal absorption into the microbiologically active moiety erythromycylamine. Erythromycylamine exerts its activity by binding to the 50S ribosomal subunits of susceptible mircoorganisms resulting in inhibition of protein synthesis. Dirithromycin/erythromycylamine has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections: Staphylococcus aureus (methicillin-susceptible strains only), Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, and Mycoplasma pneumoniae.

Dynabac Absorption

Oral dirithromycin is rapidly absorbed, with an absolute bioavailability of approximately 10%. Dietary fat has little or no effect on the bioavailability of dirithromycin.

Dynabac side effects and Toxicity

The toxic symptoms following an overdose of a macrolide antibiotic may include nausea, vomiting, epigastric distress, and diarrhea.

Dynabac Patient Information

Dynabac Organisms Affected

Enteric bacteria and other eubacteria